24 results
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 21
Results of Operations and Financial Condition
4:31pm
of the tumor micro-environment (TME) and a negative regulator (checkpoints) of immune cell functions In vivo galectin-3 inhibition reprograms tumor associated … -3 Creates an Immune Compromised Tumor Micro-Environment (TME) 24
Galectin-3 Predicts Poor Response to Pembrolizumab in NSCLC Tumour resistance
CORRESP
GLTO
Galecto Inc
20 Oct 20
Correspondence with SEC
12:00am
, 2020, including what consideration you gave to any changes in your business or the economic environment during that time.
Securities and Exchange … issued on June 24, 2020. The Company’s Board of Directors considered the following developments in the economic environment and the Company’s
UPLOAD
GLTO
Galecto Inc
19 Oct 20
Letter from SEC
12:00am
in your business or the economic
environment during that
time.
Hans T. Schambye
Galecto, Inc
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 22
Regulation FD Disclosure
4:02pm
: Galectin-3: activator and recruiter of many cell types involved in fibrosis and cancer growth in the tumor micro-environment LOXL2: a key enzyme
10-K
q25h9 my8i
29 Mar 21
Annual report
6:03am
S-1/A
EX-1.1
j5jzzwdx3
22 Oct 20
IPO registration (amended)
6:13am
10-Q
3sf76svw
11 Dec 20
Quarterly report
7:30am
S-3
EX-1.2
tchmfl2a
4 Nov 21
Shelf registration
4:59pm